Nutriband Extends Patent Coverage for AVERSA™ Technology
Nutriband has successfully patented its abuse-deterrent technology across 46 countries, enhancing global market access.
As part of its strategic growth, Nutriband is gearing up to file for FDA approval for AVERSA™ Fentanyl within the upcoming year. This marks a pivotal move for the company and its innovative approach to combating drug abuse.
New Patent Registration in Macao
Nutriband Inc. (NASDAQ:NTRB, NASDAQ:NTRBW), known for its advancements in prescription transdermal pharmaceutical products, has announced a significant milestone. The company has met all necessary requirements to extend its Chinese patent to Macao, effectively safeguarding its unique technology.
With Patent number J/9010 assigned by the Macao IP Office and an entry date noted, this new registration is crucial for Nutriband. Macao operates under its own patent system, distinct from mainland China, which offers unique opportunities for business and innovation in the region.
The Significance of AVERSA™ Technology
The AVERSA™ technology represents a breakthrough in abuse-deterrent systems. It incorporates aversive agents within transdermal patches to significantly mitigate the risks of drug abuse, misuse, and accidental exposure. This is particularly vital for drugs prone to abuse, such as opioids and stimulants, ensuring they remain accessible to those who genuinely need medical intervention.
Global Impact of AVERSA™ Technology
With patents covering prominent global markets—like the United States, Europe, Japan, and more—Nutriband's AVERSA™ technology stands out as a critical player in the pharmaceutical landscape. This wide-reaching patent portfolio firmly positions Nutriband to lead in developing solutions that prioritize safety and patient care.
Partnership with Kindeva Drug Delivery
Nutriband is collaborating with Kindeva Drug Delivery, a leading contract development firm, to bring the AVERSA™ Fentanyl product to market. This partnership integrates Nutriband’s innovative technologies with Kindeva’s expertise in FDA-approved systems, promising a more effective response to the opioid crisis.
Market Potential and Projections
The anticipation surrounding AVERSA Fentanyl is significant—it is expected to be the first opioid patch engineered to deter misuse and lower the risk of accidental exposure. Analysts project that AVERSA Fentanyl could achieve annual U.S. sales ranging from $80 million to $200 million, marking a substantial growth opportunity for Nutriband.
About Nutriband Inc.
Nutriband is dedicated to developing a robust portfolio of transdermal pharmaceuticals, with a specialized focus on abuse-deterrent solutions. The company’s AVERSA™ technology is adaptable, allowing integration into various transdermal patches to curtail the potential for drug abuse.
The company actively works to expand its product offerings while prioritizing patient safety. Their commitment to innovation is evident in the extensive patent portfolio and ongoing partnerships within the pharmaceutical industry.
Frequently Asked Questions
What does Nutriband's patent extension to Macao mean?
This extension allows Nutriband to safeguard its AVERSA™ technology in Macao, providing greater market access and protection against misuse of their products.
What is AVERSA™ technology?
AVERSA™ technology incorporates aversive agents in transdermal patches to prevent misuse, ensuring that necessary medications remain accessible to patients.
What market potential does AVERSA Fentanyl have?
Analysts estimate that AVERSA Fentanyl could see annual sales in the U.S. between $80 million and $200 million, indicating strong market interest.
Which countries are included in Nutriband's patent portfolio?
Nutriband's patent portfolio spans 46 countries, including major markets like the U.S., Japan, Canada, and parts of Europe, enhancing their global presence.
How is Nutriband responding to the opioid crisis?
Nutriband, through its AVERSA™ technology, aims to create safer opioid delivery methods to reduce abuse and accidental exposure while ensuring that essential medications are accessible.
